The Follow-on African Consortium for Tenofovir Studies (FACTS)—a vaginal microbicide follow-up to the CAPRISA 004 study—is expected to begin later this summer, The New Age reports. Funded by the South Africa department of science and technology, the U.S. government, the Bill & Melinda Gates Foundation and others, the study aims to expand on last summer's CAPRISA results, which found that women who used a gel containing 1 percent of HIV med tenofovir had 39 percent fewer infections than those using a placebo. For the FACTS study, 2,200 sexually active women between the ages of 18 and 30 will apply the gel before and after intercourse. Results from the study are expected by the end of 2013.

To read the full New Age article, click here.